Torrent Pharmaceuticals Ltd has scheduled a committee meeting on January 5, 2026, to consider and approve the issuance of secured Non-Convertible Debentures (NCDs) on a private placement basis. The proposal will be made within limits previously cleared by the company’s Board in July 2025.
Torrent Pharmaceuticals Ltd has informed that its Securities Transfer and Stakeholders Relationship Committee will meet on January 5, 2026, to deliberate on the proposed issuance of secured Non-Convertible Debentures (NCDs). The move aims to strengthen the company’s funding structure and support its growth and expansion initiatives.
Key Details And Highlights
-
The proposed NCD issuance will be on a private placement basis, in line with the company’s existing borrowing limits.
-
The committee will finalize the quantum, tenure, and terms of the debenture issue during the scheduled meeting.
-
The proposal is backed by the approval of the company’s Board of Directors given at its meeting held on July 28, 2025.
-
Such fund-raising mechanisms are commonly used by corporates to secure long-term capital at competitive rates without diluting equity.
-
The decision is expected to support Torrent Pharma’s capital requirements and ongoing financial planning.
Source: Exchange filing – BSE/NSE update by Torrent Pharmaceuticals Ltd.